Cargando…

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma

Detalles Bibliográficos
Autores principales: Saburi, Masuho, Ogata, Masao, Soga, Yasuhiro, Kondo, Yoshiyuki, Kurimoto, Ryo, Itani, Kazuhito, Kohno, Kazuhiro, Uchida, Hiroki, Nakayama, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187674/
https://www.ncbi.nlm.nih.gov/pubmed/32224561
http://dx.doi.org/10.3960/jslrt.19031
_version_ 1783527208313159680
author Saburi, Masuho
Ogata, Masao
Soga, Yasuhiro
Kondo, Yoshiyuki
Kurimoto, Ryo
Itani, Kazuhito
Kohno, Kazuhiro
Uchida, Hiroki
Nakayama, Toshiyuki
author_facet Saburi, Masuho
Ogata, Masao
Soga, Yasuhiro
Kondo, Yoshiyuki
Kurimoto, Ryo
Itani, Kazuhito
Kohno, Kazuhiro
Uchida, Hiroki
Nakayama, Toshiyuki
author_sort Saburi, Masuho
collection PubMed
description
format Online
Article
Text
id pubmed-7187674
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher JSLRT
record_format MEDLINE/PubMed
spelling pubmed-71876742020-04-29 Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma Saburi, Masuho Ogata, Masao Soga, Yasuhiro Kondo, Yoshiyuki Kurimoto, Ryo Itani, Kazuhito Kohno, Kazuhiro Uchida, Hiroki Nakayama, Toshiyuki J Clin Exp Hematop Letter to the Editor JSLRT 2020-03-28 /pmc/articles/PMC7187674/ /pubmed/32224561 http://dx.doi.org/10.3960/jslrt.19031 Text en © 2020 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.
spellingShingle Letter to the Editor
Saburi, Masuho
Ogata, Masao
Soga, Yasuhiro
Kondo, Yoshiyuki
Kurimoto, Ryo
Itani, Kazuhito
Kohno, Kazuhiro
Uchida, Hiroki
Nakayama, Toshiyuki
Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
title Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
title_full Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
title_fullStr Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
title_full_unstemmed Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
title_short Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
title_sort poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187674/
https://www.ncbi.nlm.nih.gov/pubmed/32224561
http://dx.doi.org/10.3960/jslrt.19031
work_keys_str_mv AT saburimasuho poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT ogatamasao poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT sogayasuhiro poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT kondoyoshiyuki poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT kurimotoryo poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT itanikazuhito poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT kohnokazuhiro poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT uchidahiroki poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma
AT nakayamatoshiyuki poorresponsetodaratumumabandcarfilzomibinnewlydiagnosedanaplasticmultiplemyeloma